Why Most RPM Companies Stall at $10M ARR (and What the Ones That Break Through Do Differently)

We have spent the last decade working with remote patient monitoring and chronic care management companies at every stage. The pattern we see at the $10M ARR mark is not a coincidence and it is not bad execution. It is structural.

The same playbook that gets a company to $10M is the playbook that prevents it from getting to $50M. Founders who recognize this early do something about it. The ones who do not spend two years grinding before they make the same realization the hard way.

What the stall actually looks like

The pattern is consistent across the companies we have worked with and the dozens more we have evaluated. A team builds a clean point solution, usually for a single condition (hypertension, diabetes, CHF) and a single buyer (independent primary care, FQHCs, a regional health system). They solve a real problem. Reimbursement codes line up. They build credible clinical operations and a sales motion that converts pilots to contracts.

By year three or four they are at $8–10M ARR. Then three things happen at once.

The TAM in the original niche caps out. They have already worked the relationships that closed easily. The next tier of buyers requires a longer sales cycle, more integration work, and a level of credibility their reference list cannot yet support.

Customer concentration becomes a board conversation. Two or three customers represent forty to sixty percent of revenue. Every quarterly review starts with how those relationships are doing rather than where the next ten million is coming from.

Margins compress. Device costs are not falling fast enough. Clinical labor is not elastic. Commodity competitors enter the segment and customers start asking for fifteen-percent discounts at renewal. The unit economics that worked at $5M look thinner at $10M.

None of these are surprising in isolation. What surprises founders is that they all hit at once, and the same hire-more-AEs reflex that worked at $3M does not work at $10M.

What the breakouts do differently

We have watched a smaller number of companies push through this wall to $50M+ ARR. The pattern there is also consistent. Four moves, made earlier than feels comfortable.

1. They re-architect pricing before they have to. The companies that stall are still selling per-patient-per-month at the same rate they set in their first health-system pilot. The ones that break through move to platform pricing tied to outcomes, populations, or risk-bearing arrangements. This is not a 2x price increase dressed up in new language. It is a different commercial model that aligns the customer's spend with the value the platform creates. It also future-proofs against the inevitable race-to-the-bottom on PMPM rates.

2. They expand to a second segment before the first one is "done." Founders treat segment expansion as a victory lap. The breakouts treat it as risk management. The right time to launch your second condition or second buyer type is when your first is at seventy-percent of what you think the ceiling is. Doing it earlier feels premature, but it is the only way to avoid the one to two years of stalled growth that comes from waiting until you absolutely need a new vector. We have seen this pattern with one of the companies we work with: they entered a second clinical segment while still under-penetrated in the first, and within seven months grew from five thousand to ten thousand active patients across both.

3. They build partnership architecture, not channel sales. Most RPM companies treat partnerships as a feature: an integration with one or two devices, a referral relationship with one EHR vendor. The breakouts treat partnerships as the spine of the GTM motion. They build deep, multi-year integrations with the device manufacturers, EHR systems, and ACO/MSO operators that touch their target customers every day. The result is that distribution becomes a flywheel rather than a series of one-deal-at-a-time conversations. One platform we worked with built partnerships with twenty-five-plus FDA-cleared devices and integrations with eight EHR systems before they were at $20M ARR. That investment was the reason they could credibly walk into a national health system conversation when most of their competitors could not.

4. They treat clinical operations as IP. The companies that stall view clinical operations as overhead. The ones that break through view it as the most defensible asset they own. They standardize their care models, document their workflows, train against them, and turn that operational rigor into something that can be sold and scaled. When a buyer asks "what do you actually do for the patient," they have an answer that is more specific than the next vendor in the RFP. This is also what makes the eventual transition to risk-bearing arrangements possible. You cannot take risk on populations you do not have a defined clinical playbook for.

What it costs to make these moves

None of this is free. The pricing re-architecture means harder commercial conversations and some lost deals in the short term. The second-segment launch consumes engineering and clinical capacity that the existing customer base would happily absorb. The partnership investments take twelve to eighteen months to pay back. The clinical operations work is not glamorous, and most VCs do not get excited about it.

But the alternative is the $10M plateau. We have watched companies sit at the same ARR for eighteen months while the team grows frustrated, the board grows impatient, and the next round of capital becomes harder to raise on terms that anyone wants. The stall is far more expensive than the moves that prevent it.

How to know you are heading there

If you are running an RPM or CCM company today, a few honest questions:

• What percentage of next year's revenue is committed from your existing customer base, versus dependent on net-new acquisition?
• If your top three customers all renewed at the same PMPM in twelve months, are you still hitting plan?
• What is your pricing conversation with a national health system, and is it the same conversation you had with your first regional buyer?
• If your two strongest competitors raised $50M tomorrow and bought market share with discounted pricing, what changes in your model?
• Is there a single workflow you can put on a whiteboard and explain in three minutes that captures what your clinical team actually does?

If those questions are uncomfortable, you are not alone, and you are not late. Most companies we work with face some version of all five. The work is identifying which of the four moves matters most given where the company is, and sequencing them in a way the team can actually execute.

That is the work we do. If you are anywhere near this stage and any of this resonated, we would love to hear from you.

— Andrew